Randomized controlled trial of Fluoxetine or placebo on quality of life after acute ischemic stroke.
Not Applicable
- Conditions
- Ischemic stroke
- Registration Number
- TCTR20181216001
- Lead Sponsor
- Bhumibol Adulyadej Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- consenting
- age > 18
- acute ischemic stroke patient
Exclusion Criteria
- history of or current psychiatric condition
- hemorrhagic complication
- EQ-5D-5L score > 0.9
- language barrier
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life 3 months EQ-5D-5L ,Post stroke depression 3 months Thai HADS
- Secondary Outcome Measures
Name Time Method Post stroke depression 3 months Thai HADS,Disability 3 months Modified Rankin Score
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Fluoxetine's effects on post-stroke neuroplasticity and inflammation in TCTR20181216001?
How does Fluoxetine compare to standard-of-care treatments like tPA in improving quality of life after acute ischemic stroke?
Which biomarkers, such as BDNF or inflammatory cytokines, predict response to Fluoxetine in TCTR20181216001 stroke patients?
What adverse events are associated with Fluoxetine use in acute ischemic stroke recovery, and how are they managed?
Are there combination therapies or alternative SSRIs (e.g., sertraline) with Fluoxetine for post-stroke quality of life in clinical research?